FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, [D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kharabi Darius						2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [KALA]									eck all appli Directo	cable) or	10% Owner		vner	
(Last)	`	(First) (Middle) A PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/22/2023								below)			Other (s below)	` ´	
1167 MASSACHUSETTS AVENUE					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	GTON M	ÍΑ	02476												X Form filed by One Reporting Person Form filed by More than One Reporting Person				- 1	
(City) (State) (Zip)				_	Rule 10b5-1(c) Transaction Indication															
									icate that a tr defense cor							on or written	plan t	that is intende	ed to	
		Tab	le I - Noi	า-Deriv	ative	Se	curities	s Ac	quired, [Disp	osed c	of, or B	ene	ficial	ly Owned	t				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Transaction Dispo		Dispose	urities Acquired (A) o sed Of (D) (Instr. 3, 4			Benefici	es Form ially (D) of Following (I) (II		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D) P		Price	Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock ⁽¹⁾ 06/22				2/2023	/2023		A		36,84	47 A		\$ <mark>0</mark>	61,9	61,902(2)		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transactio Code (Inst 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Ni of	umber						
Stock Option (right to	\$14.56	06/22/2023			A		49,129		(3)	06	5/21/2033	Commo Stock	n 49	9,129	\$0	49,129)	D		

Explanation of Responses:

- 1. Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2024. 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
- 2. Includes 49,020 unvested RSUs.
- 3. This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

/s/ Eric Trachtenberg, Attorney-in-Fact

** Signature of Reporting Person Date

06/23/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.